Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

G Morad, BA Helmink, P Sharma, JA Wargo - Cell, 2021 - cell.com
Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors

A Chennamadhavuni, L Abushahin, N Jin… - Frontiers in …, 2022 - frontiersin.org
Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …

T cells specific for α-myosin drive immunotherapy-related myocarditis

ML Axelrod, WC Meijers, EM Screever, J Qin… - Nature, 2022 - nature.com
Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …

Immune-related adverse events and the balancing act of immunotherapy

M Conroy, J Naidoo - Nature communications, 2022 - nature.com
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …

Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer

B Shankar, J Zhang, AR Naqash, PM Forde… - JAMA …, 2020 - jamanetwork.com
Importance The spectrum of individual immune-related adverse events (irAEs) from anti–
programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune …

Tumor mutational burden quantification from targeted gene panels: major advancements and challenges

L Fancello, S Gandini, PG Pelicci… - Journal for immunotherapy …, 2019 - Springer
Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is
emerging as a promising biomarker for immunotherapy response in cancer patients. TMB …

Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases

A Tison, S Garaud, L Chiche, D Cornec… - Nature Reviews …, 2022 - nature.com
Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

Harnessing big data to characterize immune-related adverse events

Y Jing, J Yang, DB Johnson, JJ Moslehi… - Nature Reviews Clinical …, 2022 - nature.com
Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …

[HTML][HTML] Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors

E De Martin, JM Michot, O Rosmorduc, C Guettier… - JHEP Reports, 2020 - Elsevier
Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …

Intratumoral immunotherapy: from trial design to clinical practice

S Champiat, L Tselikas, S Farhane, T Raoult… - Clinical Cancer …, 2021 - AACR
Systemic immunotherapies such as immune checkpoint blockade targeted at PD (L) 1 and
CTLA4 have demonstrated their ability to provide durable tumor responses and long-term …